Research shows that GLP-1 medications like semaglutide can lead to dramatic early weight loss, but plateaus typically occur after several months, requiring a new, physician-guided approach for continued success
Ongoing Phase 3 trials are evaluating retatrutide in knee osteoarthritis (where weight-independent anti-inflammatory effects have been observed), obstructive sleep apnea, and non-alcoholic steatohepatitis
Results: Age, gender, history of gastrointestinal disorders, and number of combined oral medications were found as risk factors for the occurrence of GISEs in patients with T2DM using GLP-1RAs ( p 0.05 for the validation set)
The investment ranges from minimal (basic ice application) to substantial (whole-body cryotherapy chambers), depending on the approach selected
R.TammaliR.BorrokM.HurtE.et al (2018)
When combined with a personalized nutrition and lifestyle plan, Semaglutide can lead to significant and lasting weight loss